FDA grants designation as Breakthrough Device

The US Food and Drug Administration (FDA) has granted fast track access to PentraSorb CRP as a regenerable adsorbent in the indication of STEMI (severe subacute myocardial infarction) through the Breakthrough Device Program. A very notable milestone towards US approval for the treatment of heart attacks.